Titre : Biodisponibilité

Biodisponibilité : Questions médicales fréquentes

Termes MeSH sélectionnés :

Learning Disabilities
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Biodisponibilité : Questions médicales les plus fréquentes", "headline": "Biodisponibilité : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Biodisponibilité : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-31", "dateModified": "2025-04-25", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Biodisponibilité" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pharmacocinétique", "url": "https://questionsmedicales.fr/mesh/D010599", "about": { "@type": "MedicalCondition", "name": "Pharmacocinétique", "code": { "@type": "MedicalCode", "code": "D010599", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G07.690.725" } } }, "about": { "@type": "MedicalCondition", "name": "Biodisponibilité", "alternateName": "Biological Availability", "code": { "@type": "MedicalCode", "code": "D001682", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "William Green", "url": "https://questionsmedicales.fr/author/William%20Green", "affiliation": { "@type": "Organization", "name": "York Health Economics Consortium, York, UK." } }, { "@type": "Person", "name": "Richard Stork", "url": "https://questionsmedicales.fr/author/Richard%20Stork", "affiliation": { "@type": "Organization", "name": "Almirall, Uxbridge, UK." } }, { "@type": "Person", "name": "Aina Pi Blanque", "url": "https://questionsmedicales.fr/author/Aina%20Pi%20Blanque", "affiliation": { "@type": "Organization", "name": "Almirall S.A, Barcelona, Spain." } }, { "@type": "Person", "name": "Ayeda Nadeem", "url": "https://questionsmedicales.fr/author/Ayeda%20Nadeem", "affiliation": { "@type": "Organization", "name": "York Health Economics Consortium, York, UK." } }, { "@type": "Person", "name": "Morgane C Mouslim", "url": "https://questionsmedicales.fr/author/Morgane%20C%20Mouslim", "affiliation": { "@type": "Organization", "name": "The Center for Drug Safety and Effectiveness and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "How Do Intermediate Grade Students With and Without Language-Based Learning Disabilities Use Noun Phrases in Narrative Writing?", "datePublished": "2023-06-20", "url": "https://questionsmedicales.fr/article/37338979", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1044/2023_AJSLP-22-00331" } }, { "@type": "ScholarlyArticle", "name": "Improving access to primary care and annual health checks for people who have a learning disability: a multistakeholder qualitative study.", "datePublished": "2022-12-23", "url": "https://questionsmedicales.fr/article/36564116", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-065945" } }, { "@type": "ScholarlyArticle", "name": "Evaluating the nutrition and body mass index clinical link pathway in mental health and learning disability services: A mixed-methods study.", "datePublished": "2024-06-13", "url": "https://questionsmedicales.fr/article/38870198", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0303893" } }, { "@type": "ScholarlyArticle", "name": "Maternal smoking cessation in the first trimester still poses an increased risk of attention-deficit/hyperactivity disorder and learning disability in offspring.", "datePublished": "2024-07-16", "url": "https://questionsmedicales.fr/article/39081356", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2024.1386137" } }, { "@type": "ScholarlyArticle", "name": "A protocol to identify the barriers and facilitators for people with severe mental illness and/or learning disabilities for PErson Centred Cancer Screening Services (PECCS).", "datePublished": "2022-11-30", "url": "https://questionsmedicales.fr/article/36449513", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0278238" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques", "item": "https://questionsmedicales.fr/mesh/D010829" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes pharmacologiques et toxicologiques", "item": "https://questionsmedicales.fr/mesh/D002620" }, { "@type": "ListItem", "position": 4, "name": "Pharmacocinétique", "item": "https://questionsmedicales.fr/mesh/D010599" }, { "@type": "ListItem", "position": 5, "name": "Biodisponibilité", "item": "https://questionsmedicales.fr/mesh/D001682" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Biodisponibilité - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Biodisponibilité", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Biodisponibilité", "description": "Comment évaluer la biodisponibilité d'un médicament ?\nQuels tests sont utilisés pour mesurer la biodisponibilité ?\nLa biodisponibilité est-elle la même pour tous les médicaments ?\nQuels facteurs influencent la biodisponibilité ?\nComment la biodisponibilité est-elle mesurée ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Biodisponibilité", "description": "Quels symptômes indiquent une faible biodisponibilité ?\nPeut-on ressentir des effets secondaires d'une biodisponibilité élevée ?\nComment la biodisponibilité affecte-t-elle les symptômes ?\nLes symptômes varient-ils selon la voie d'administration ?\nQuels symptômes peuvent indiquer une surdose liée à la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Biodisponibilité", "description": "Comment prévenir une biodisponibilité faible ?\nL'alimentation influence-t-elle la biodisponibilité ?\nQuelles habitudes de vie favorisent une bonne biodisponibilité ?\nLes médicaments doivent-ils être pris à jeun ?\nComment éviter les interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Biodisponibilité", "description": "Comment améliorer la biodisponibilité d'un médicament ?\nQuels traitements augmentent la biodisponibilité ?\nLes médicaments à libération prolongée affectent-ils la biodisponibilité ?\nComment la biodisponibilité influence-t-elle le choix du traitement ?\nLes suppléments nutritionnels affectent-ils la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Biodisponibilité", "description": "Quelles complications peuvent résulter d'une biodisponibilité élevée ?\nUne biodisponibilité faible peut-elle causer des complications ?\nComment les complications sont-elles liées à la biodisponibilité ?\nLes complications peuvent-elles être évitées par une bonne biodisponibilité ?\nQuels sont les risques de surdosage liés à la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Biodisponibilité", "description": "Quels facteurs augmentent le risque d'une biodisponibilité faible ?\nLe tabagisme affecte-t-il la biodisponibilité ?\nLes maladies chroniques influencent-elles la biodisponibilité ?\nL'âge influence-t-il la biodisponibilité ?\nLes habitudes alimentaires affectent-elles la biodisponibilité ?", "url": "https://questionsmedicales.fr/mesh/D001682?mesh_terms=Learning+Disabilities&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer la biodisponibilité d'un médicament ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des études pharmacocinétiques pour mesurer la concentration dans le sang." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer la biodisponibilité ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des études de bioéquivalence sont couramment utilisés." } }, { "@type": "Question", "name": "La biodisponibilité est-elle la même pour tous les médicaments ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle varie selon la voie d'administration et la formulation du médicament." } }, { "@type": "Question", "name": "Quels facteurs influencent la biodisponibilité ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'alimentation, le pH gastrique et la présence d'autres médicaments peuvent l'affecter." } }, { "@type": "Question", "name": "Comment la biodisponibilité est-elle mesurée ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle est mesurée par le rapport entre la concentration plasmatique et la dose administrée." } }, { "@type": "Question", "name": "Quels symptômes indiquent une faible biodisponibilité ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes d'inefficacité du traitement, comme la persistance de la maladie." } }, { "@type": "Question", "name": "Peut-on ressentir des effets secondaires d'une biodisponibilité élevée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une biodisponibilité élevée peut entraîner des effets secondaires plus marqués." } }, { "@type": "Question", "name": "Comment la biodisponibilité affecte-t-elle les symptômes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une biodisponibilité insuffisante peut retarder la réponse thérapeutique et aggraver les symptômes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon la voie d'administration ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon que le médicament est pris par voie orale ou intraveineuse." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une surdose liée à la biodisponibilité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes tels que nausées, vertiges ou confusion peuvent indiquer une surdose." } }, { "@type": "Question", "name": "Comment prévenir une biodisponibilité faible ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "En respectant les recommandations d'administration et en évitant les interactions médicamenteuses." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la biodisponibilité ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains aliments peuvent augmenter ou diminuer la biodisponibilité des médicaments." } }, { "@type": "Question", "name": "Quelles habitudes de vie favorisent une bonne biodisponibilité ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une hydratation adéquate et une alimentation équilibrée peuvent favoriser une bonne biodisponibilité." } }, { "@type": "Question", "name": "Les médicaments doivent-ils être pris à jeun ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend du médicament; certains nécessitent d'être pris à jeun pour une meilleure biodisponibilité." } }, { "@type": "Question", "name": "Comment éviter les interactions médicamenteuses ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "En consultant un professionnel de santé avant de prendre plusieurs médicaments simultanément." } }, { "@type": "Question", "name": "Comment améliorer la biodisponibilité d'un médicament ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "On peut utiliser des formulations spécifiques ou des co-administrations pour l'optimiser." } }, { "@type": "Question", "name": "Quels traitements augmentent la biodisponibilité ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sous forme injectable ont généralement une biodisponibilité plus élevée." } }, { "@type": "Question", "name": "Les médicaments à libération prolongée affectent-ils la biodisponibilité ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent améliorer la biodisponibilité en libérant le principe actif sur une période prolongée." } }, { "@type": "Question", "name": "Comment la biodisponibilité influence-t-elle le choix du traitement ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elle guide le choix de la voie d'administration et la posologie pour maximiser l'efficacité." } }, { "@type": "Question", "name": "Les suppléments nutritionnels affectent-ils la biodisponibilité ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains suppléments peuvent interagir et modifier la biodisponibilité des médicaments." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter d'une biodisponibilité élevée ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Une biodisponibilité élevée peut entraîner des effets indésirables graves ou une toxicité." } }, { "@type": "Question", "name": "Une biodisponibilité faible peut-elle causer des complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner un échec thérapeutique et des complications liées à la maladie." } }, { "@type": "Question", "name": "Comment les complications sont-elles liées à la biodisponibilité ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications surviennent souvent lorsque la concentration du médicament est insuffisante ou excessive." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées par une bonne biodisponibilité ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une biodisponibilité adéquate peut réduire le risque de complications liées au traitement." } }, { "@type": "Question", "name": "Quels sont les risques de surdosage liés à la biodisponibilité ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un surdosage peut survenir si la biodisponibilité est trop élevée, entraînant des effets toxiques." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'une biodisponibilité faible ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, les maladies gastro-intestinales et les interactions médicamenteuses peuvent l'augmenter." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il la biodisponibilité ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut modifier le métabolisme des médicaments, affectant leur biodisponibilité." } }, { "@type": "Question", "name": "Les maladies chroniques influencent-elles la biodisponibilité ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme le diabète ou l'insuffisance hépatique peuvent altérer la biodisponibilité." } }, { "@type": "Question", "name": "L'âge influence-t-il la biodisponibilité ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir une biodisponibilité modifiée en raison de changements physiologiques." } }, { "@type": "Question", "name": "Les habitudes alimentaires affectent-elles la biodisponibilité ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en graisses ou en fibres peut influencer la biodisponibilité des médicaments." } } ] } ] }

Sources (10000 au total)

How Do Intermediate Grade Students With and Without Language-Based Learning Disabilities Use Noun Phrases in Narrative Writing?

Noun phrase usage and elaboration is an important feature of literate language. In this study, we described noun phrase usage and elaboration in the narrative writing samples of intermediate grade stu... Narrative writing samples from 64 students in fourth through sixth grades were coded for five types of noun phrases using coding procedures adapted from prior research. Noun phrase ratios (NPR) were c... Students in this study included all five types of noun phrases in their narrative writing to varying degrees. Between-group differences were observed in the frequency of complex noun phrase usage. Sig... Noun phrase usage is an important consideration for both theoretical and clinical purposes. Findings from this study are related to theoretical models of writing and levels of language frameworks. The...

Improving access to primary care and annual health checks for people who have a learning disability: a multistakeholder qualitative study.

To investigate key stakeholders' views on how to improve access to primary care in general practice settings for people with learning disabilities (or intellectual disabilities). Further to explore ho... A qualitative study design was used with data collected during focus groups, interviews and open-response surveys; data analysis was thematic and informed by stakeholder consultation. Processes to fac... UK regional services including learning disability organisations, primary care general practitioner (GP) clinical practice networks and supported housing organisations.... Sixteen people participated in the study: four people with learning disabilities participated in a focus group; four relatives completed an interview or survey; eight GPs, practice nurses and supporte... Five overarching themes describing approaches to improve primary care access for people with learning disabilities were identified including: prioritisation, proactivity, innovation and improvement, p... All stakeholders identified problems, with primary care interfaces being misaligned with the needs of people with learning disabilities. The recommendations informed by all stakeholders can be used to...

Maternal smoking cessation in the first trimester still poses an increased risk of attention-deficit/hyperactivity disorder and learning disability in offspring.

Studies have found maternal smoking during pregnancy was linked to attention-deficit/hyperactivity disorder (ADHD) risk. It is unclear if maternal smoking cessation during pregnancy lowers ADHD and le... Data from the National Health and Nutrition Examination Survey 1999-2004 (8,068 participants) were used. Logistic regression was used to analyze the associations between maternal smoking and smoking c... Compared to non-smokers' offspring, maternal smoking during pregnancy increased the risk of ADHD (odds ratios [OR] = 2.07, 95% confidence interval [CI]: 1.67-2.56) and LD (OR = 1.93, 95% CI: 1.61-2.31... Maternal smoking cessation in the first trimester still poses an increased risk of ADHD and LD in offspring. Furthermore, it seems that the later the mothers quit smoking during pregnancy, the higher ...

A protocol to identify the barriers and facilitators for people with severe mental illness and/or learning disabilities for PErson Centred Cancer Screening Services (PECCS).

To identify the barriers and facilitators that people with severe mental illness and people with learning disabilities may encounter when accessing cancer screening and make recommendations for implem... An 18-month sequential, mixed-methods study comprising of two phases of work and underpinned by Normalisation Process Theory, recruiting from across the North-East and North Cumbria. The first phase a... This study has received Teesside University ethical approval, Health Research Authority approval (IRAS: 310622) and favourable opinion (REF: 22/PR/0793). Findings will be disseminated through a range ...

'Why are we stuck in hospital?' Understanding delayed hospital discharges for people with learning disabilities and/or autistic people in long-stay hospitals in the UK.

Despite longstanding efforts at de-institutionalisation, around 2000 people with learning disabilities and/or autistic people in England currently live in hospital settings, amidst reports of protract...

Joint effect of docosahexaenoic acid intake and tobacco smoke exposure on learning disability in children and adolescents: a cross-sectional study from the NHANES database.

Docosahexaenoic acid (DHA) has been reported to be associated with the children's neurodevelopment, who may be exposed to tobacco smoke simultaneously. The evidence about joint effect of DHA intake an... A cross-sectional analysis of the NHANES 1999-2004 was performed. Children and adolescents aged 6-15 years old were included. The outcome was diagnosed by parental report of ever health professionals ... We identified 5,247 children and adolescents in present study, of whom 593 (11.30%) had LD. After adjusting covariates, we observed children and adolescents with DHA intake (OR = 0.76, 95%CI: 0.61-0.9... Increasing the DHA intake and reducing tobacco smoke exposure may have a potential role in the prevention of LD in children and adolescents. This joint effect warrants further investigation by large-s...

Incidence and risk of attention-deficit/hyperactivity disorder and learning disability by adulthood after traumatic brain injury in childhood: a population-based birth cohort study.

The aim of this study was to understand the risk of developing attention-deficit/hyperactivity disorder (ADHD) or learning disability (LD) after childhood traumatic brain injury (TBI) in a population-...

Mother and Daughter with Short Stature, Microcephaly, Mild Dysmorphic Features, and Learning Disabilities Due to Ververi-Brady Syndrome Associated with a New Variant of the QRICH1 Gene.

BACKGROUND Ververi-Brady syndrome (VEBRAS) is an autosomal dominant condition associated with short stature, microcephaly, mild dysmorphic features, and learning disabilities. It was first described i...

Hospital admissions of school-age children with an intellectual disability: A population-based survey.

To describe the profiles of hospital admissions of school-age children identified with a learning disability (ICD-11 intellectual developmental disorder) and/or safeguarding needs compared to children... Data were collected about the reasons for and duration of hospital admissions of school-age children living in the study catchment area between April 2017 and March 2019; the presence (or absence) of ... Of 46 295 children in the local population, 1171 (2.53%) had a learning disability flag. The admissions of 4057 children were analysed (1956 females; age range 5-16 years, mean 10 years 6 months, SD 3... Children with learning disabilities and/or safeguarding needs have higher rates of hospital admissions than children without. Robust identification of learning disabilities in childhood is required to... Children with learning disabilities must be consistently identified in populations so that their needs are made visible. Information about these needs must be collected from educational, health, and s...